Today’s AI Top Pick: USNA

8/13/2026 · Low Float Bullish Consensus Deep Rotation screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Today's pick · Low Float Bullish Consensus Deep RotationUSNABUY NOW8.2 / 108/13/2026

USANA Health Sciences (USNA) is the cleanest low-float setup on the board today because it is the only name where all four available timeframes point up together while price sits near the floor of its recent range. The 1h forecast is +0.56/+42.29/+50.31, the 4h is +2.88/+50.15/+39.9, the 1d is +31.35/+58.10/+65.02, and even the 1wk is +19.5/+16.33/+36.56 — that is textbook multi-timeframe agreement with kronos bullish_prob 1.0 and near_term_bullish 1.0. Nothing else on the list shows every horizon confirming. Crucially, we are not chasing. USNA is in the 4.23rd percentile of its 21-bar daily range with a −39.97% drawdown, RSI is deeply oversold at 25.41, and the 21-bar weekly position is 0. That is a coiled spring, not an extension. Compare that to MORN (100th percentile, negative near-term forecasts) or TASK (94.8 4h percentile, tiny near-term forecast) — those are late, USNA is early. Fundamentals are respectable for a beaten-down small cap: fwdPe 7.65, debt/equity 0, gross margin 74.74%, operating margin +4.54%, epsNextY estimate +132.89%, and analyst targetUpsidePct +84.6%. The wart is a small profitMargin of −2.43% and a lukewarm recom of 3, so this is a value/turnaround setup, not a growth darling. Recent news (Q2 earnings call, StockStory's 'risky Russell 2000' piece) is mixed but not materially negative — no dilution announcement, no guidance cut, no lawsuit. That is why we buy today rather than wait: the pullback is already this deep, sentiment is already skeptical, and the forecast tape is broad-based. Runners-up were considered and passed on for specific reasons: GPI has better fundamentals (PE 11.1, PEG 0.85, +40% mid-tf forecasts) but caught a Morgan Stanley downgrade on 8/8 and its 1wk short forecast is only +1.51%, indicating the higher-timeframe trend hasn't turned. BESS has strong forecasts but no profitability data. GRCE just announced a $10M private placement (dilution). CDNL had TWO price-target cuts this week. USNA has none of those landmines.

Entry zone

$13.60 – $14.20 (current $13.95, buy into weakness given RSI 25.41)

Stop loss

$12.40 (below the recent low; ~11% risk, protects against a break of the 21-bar floor at pos 0)

First target

$16.60 (+19% — aligned with 1wk fc_short +19.5% and 1d fc_short +31%)

Longer target

$21.50 – $23.00 (+55–65% — aligned with 1d fc_long +65.02% and 4h fc_mid +50.15%)

Risks

Consensus recom is 3.0 (Hold), not Buy — analyst support is passive at best and the fundamental_score is only 2.5
Profit margin is −2.43% and 1-year performance is −54.97%; the fundamental turnaround is not yet proven on the P&L
RSI 25.41 and position 0 on the weekly means the downtrend is still intact — a knife-catch until price reclaims $15
Short float 6.33% is modest but MLM/personal-care sector faces secular headwinds (StockStory flagged as 'risky' 8/10)
1h fc_short is only +0.56%; there may be another 1–3% flush before the reversal triggers

Honorable mentions

GPIBest fundamentals in the pool (PE 11.1, PEG 0.85, fwdPe 6.05, profitable) with position at 0–1.35% of range and 4h/1d mid-tf forecasts of +40%. Downgraded to buy-pullback because Morgan Stanley just downgraded 8/8 and the 1wk short forecast is only +1.51%, so the weekly trend hasn't confirmed yet.

BESSUtilities micro-cap with 4h forecasts of +75/79/68% and positive catalysts (Zach Dell backing, $6.4M cash received, Wildfire BESS project selection). Held back from #1 by lack of profitability data, recent 1d position at 97th percentile of range, and small marketCap of $25M making it more speculative than USNA.

Full ranking (30)

#	Symbol	Verdict	Score	Read
1	USNA	BUY NOW	8.2	All 4 timeframes bullish, RSI 25 oversold at range floor, fwdPe 7.65 with zero debt — cleanest multi-tf setup on the board.
2	GPI	BUY NOW	7.6	Best fundamentals (PE 11, PEG 0.85) at 1% of 21-bar range with +40% mid-tf forecasts; Morgan Stanley downgrade is the only wart.
3	BESS	BUY NOW	7.0	4h forecasts of +75/79/68% plus $6.4M cash catalyst and Wildfire project selection.
4	CCB	BUY NOW	6.7	1d fc +39/87/85% off a −39% drawdown at 23rd percentile with insider buying and TD Cowen Buy reiteration.
5	AZO	BUY PULLBACK	6.4	Strong fundamentals (profitMargin 12.4%, recom 1.42) but 1wk forecast turns negative; wait for weekly base to build.
6	LBRDA	BUY NOW	6.2	1d forecasts +13/50/61% with fwdPe 5.82; already reclaimed 4h/1d trend, position 70–78% is only slight concern.
7	MORN	WAIT	5.9	Best fundamental_score at 7.25 but stretched at 100th percentile with negative near-term forecasts — no entry today.
8	TASK	WAIT	5.7	PE 5.99 and positive analyst tone but 4h position 94.81 and 1wk fc short is −0.23% — too extended.
9	CNCK	BUY PULLBACK	5.6	Q1 beat and Japan crypto tailwind but 1wk forecasts (+174/369/409%) look like extreme outliers, prefer a dip.
10	IDN	BUY PULLBACK	5.5	Profitable tech (roe 11.38, PM 9.56) with 4h fc +47/51/62% but 1wk drawdown −56% shows structural damage.
11	ANNA	BUY PULLBACK	5.4	Profitable energy (PM 17.43%, salesYoY +1533%) but weekly drawdown −69.57%; SeekingAlpha bullish thesis needs confirmation.
12	GLMD	BUY PULLBACK	5.2	Aramchol Parkinson's and cardiac catalysts; 4h/1d forecasts constructive but micro-cap $4.6M means dilution risk always looms.
13	QNTM	BUY PULLBACK	5.1	FDA clearance for MS trial 8/12 is a real catalyst but 4h position 47 and recent debt settlement create overhang.
14	IPWR	WAIT	4.9	1d at 100th percentile with 4h fc_mid −11.18% — extended after +62.85% weekly move.
15	PROP	AVOID	4.8	91.33% short float and 1222 debt/equity is a powder keg either way; 1d fc_short −4.42% doesn't confirm.
16	CRVO	BUY PULLBACK	4.8	HC Wainwright reiterated Buy $25 but Q2 EPS miss and Canaccord PT cut; wait for pullback from 88 percentile daily.
17	BCDA	BUY PULLBACK	4.6	Japan/US regulatory wins are real but −65% 4h drop and $13M market cap make this a lottery ticket.
18	DRMA	WAIT	4.5	Popped 27% pre-market 8/12; 1wk forecast of +25000% is an obvious data outlier, don't chase.
19	LTRN	WAIT	4.4	Open-Medicine AI spin-out and EMA clearance are positive but 4h forecasts −4.25/+2.42% don't confirm entry.
20	XTLB	WAIT	4.3	$6.4M micro-cap with strong 1wk forecasts but 1d fc_short only +0.61%; no near-term catalyst identified.
21	EVGN	WAIT	4.2	PCSK9 partnership positive but 4h position 72.98 after +50% run — chase risk high.
22	GRCE	AVOID	4.0	Just announced $10M private placement 8/5 — direct dilution overhang overrides the FDA clarity.
23	TNXP	WAIT	3.9	TONMYA surging is real but 1wk fc of +43056% is unusable data; 1d fc_short only +1.98%.
24	LUCY	WAIT	3.8	$6.2M market cap and recom 3; 4h drawdown −47% and profit margin −272% too speculative.
25	PRSO	WAIT	3.7	Q2 call today but salesYoY −38.47% and profit margin −85% with $10M cap — no fundamental support.
26	INDP	AVOID	3.6	−65.92% 4h drop and ROE −931% with no revenue; forecast +100% is dead-cat territory.
27	NXL	AVOID	3.5	Profit margin −3022%, $7.8M cap, operMargin −3084% — pure lottery ticket even with forecast.
28	YCBD	AVOID	3.3	1d fc_short −13.79% at 88th percentile of 21-bar range means we're buying the top of a bounce.
29	USBC	AVOID	3.1	1d fc_short −27.12% contradicts the bullish label; 11011% targetUpsidePct is a data artifact.
30	CDNL	AVOID	2.8	Both Stifel AND Oppenheimer cut price targets 8/12 and Q2 profitability slipped — actively deteriorating.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord